Developing novel complement activation assays for application in basic and clinical research
Studying the cross-talk between complement and TLRs, in particular to the co-receptor CD14
Investigating the effect on inflammation by inhibiting complement activation and CD14 using human whole blood in vitro models and in vivo animal models of human diseases
Studying the “Thromboinflammation” and new complex whole blood models to reveal cross-talk between biological systems ex vivo
Studying complement activation in patients with diseases being tentative candidates for future complement intervention
Develop tools for evaluation of the effect of complement therapy in the clinic
Recent publications
Mollnes TE, Storm BS, Brekke OL, Nilsson PH, Lambris JD(2022) Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research - 20 years of experience and future perspectives Semin Immunol, 101604(in press) DOI 10.1016/j.smim.2022.101604, PubMed 35570131
Emblem Å, Knutsen E, Jørgensen TE, Fure H, Johansen SD, Brekke OL, Mollnes TE, Karlsen BO(2022) Blood Transcriptome Analysis of Septic Patients Reveals a Long Non-Coding Alu-RNA in the Complement C5a Receptor 1 Gene Noncoding RNA, 8(2) DOI 10.3390/ncrna8020024, PubMed 35447887
Quach HQ, Johnson C, Ekholt K, Islam R, Mollnes TE, Nilsson PH(2022) Platelet-Depletion of Whole Blood Reveals That Platelets Potentiate the Release of IL-8 From Leukocytes Into Plasma in a Thrombin-Dependent Manner Front Immunol, 13, 865386 DOI 10.3389/fimmu.2022.865386, PubMed 35444648